Etoricoxib/tizanidine - Merck Sharp & Dohme

Drug Profile

Etoricoxib/tizanidine - Merck Sharp & Dohme

Alternative Names: Etoricoxib/tizanidine MR; Immediate-release etoricoxib/modified-release tizanidine - Merck; MK-0663B; Tizanidine/etoricoxib

Latest Information Update: 16 Jul 2016

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Merck Sharp & Dohme
  • Class Antirheumatics; Antispastics; Imidazolines; Muscle relaxants; Non-opioid analgesics; Pyridines; Small molecules; Sulfones
  • Mechanism of Action Alpha 2 adrenergic receptor agonists; Cyclo-oxygenase 2 inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • No development reported Musculoskeletal pain

Most Recent Events

  • 16 Jul 2016 No recent reports of development identified for preclinical development in Musculoskeletal-pain in USA (PO, Tablet)
  • 01 Apr 2015 Merck terminates a phase III trial for Back pain in USA prior to enrolment (NCT01979510)
  • 08 Nov 2013 Merck plans a phase III trial for Back pain in USA (NCT01979510)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top